Jaffre et al_Circulation-2019.pdf

Here we used iPSC-derived cardiomyocytes and CRISPR-Cas9 to delineate the molecular mechanisms underlying hypertrophic cardiomyopathy in Noonan syndrome individuals with a mutation in RAF1.